Activation of recombinant NAMPT (unknown origin) assessed as relative AUC at 10 uM incubated for 20 mins by fluorometric analysis relative to NAT (Rvb = 100%)
Cytotoxicity against human U2OS cells assessed as effect on cell viability up to 10 uM measured after 72 hrs by Celltiter-glo luminescent cell viability assay
Cytotoxicity against human T98G cells assessed as effect on cell viability up to 10 uM measured after 72 hrs by Celltiter-glo luminescent cell viability assay
Cytotoxicity against human SH-SY5Y cells assessed as effect on cell viability up to 10 uM measured after 72 hrs by Celltiter-glo luminescent cell viability assay
Cytotoxicity against human HepG2 cells assessed as effect on cell viability up to 10 uM measured after 72 hrs by Celltiter-glo luminescent cell viability assay
Cytoprotective activity against FK866- induced cell death in human U2OS cells assessed as increase in viable cells by measuring relative AUC at 10 uM incubated for 20 mins by fluorometric analysis relative to NAT
Neuroprotective activity against chemotherapy-induced peripheral neuropathy C57BL/6J mouse model assessed as increase in paw withdrawal threshold at 30 mg/kg, iv qd administered for 2 week followed by taxol treatment on day 9, 11, 13 and measured after 2 days by von Frey filament assay
Neuroprotective activity against chemotherapy-induced peripheral neuropathy C57BL/6J mouse model assessed as decrease in myelinated fiber damage at 30 mg/kg, iv qd administered for 2 week followed by taxol treatment on day 9, 11, 13 measured after 3 days by TEM imaging
Neuroprotective activity against chemotherapy-induced peripheral neuropathy C57BL/6J mouse model assessed as increase of NAD level in sciatic nerve tissue at 30 mg/kg, iv qd administered for 2 week followed by taxol treatment on day 9, 11, 13 measured after 3 days by TEM imaging